Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CK0802
- Development stage
- Phase 2
- Lead developer
- Cellenkos
- Modality
- Regulatory T Cells (Tregs) → Immune Effector Cells → Other Cell Types → Cell Therapies
- Administration
- Intravenous
01
Overview
CK0802 is an allogeneic, off-the-shelf cell therapy product composed of regulatory T cells (Tregs) derived from clinical-grade umbilical cord blood units. It is administered intravenously and developed using Cellenkos' proprietary CRANE technology. The primary mechanism involves the adoptive transfer of healthy Treg cells to restore immune homeostasis and restrict inflammation-induced tissue damage, particularly in the lungs. CK0802 targets integrin alpha4 (CD49d), acting as a CD49d antagonist and serving as a replacement for dysfunctional or depleted T lymphocytes. Its main indication under investigation has been COVID-19-associated acute respiratory distress syndrome (ARDS), with additional exploration in lung injury and amyotrophic lateral sclerosis[1][3][4][5][7].
- Other names
- Cryopreserved Cord Blood Derived T-Regulatory Cells
Beyond the preview
Go deeper on CK0802.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CK0802.